Author

K. Chayama

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3 Microbiology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 5 Approach:experimental assay· 3 Research Focus:host-pathogen & immune response· 2 Approach:statistical model· 2 Assay:whole-genome sequencing· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1

Frequent Co-Authors

H. Nakagawa· 3 shared A. Murayama· 2 shared A. Ono· 2 shared H. Aikata· 2 shared H. H. Aly· 2 shared H. Yamaue· 2 shared K. Shimotohno· 2 shared K. Wakae· 2 shared

Activity by Year

2017-2021 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

H. Nakagawa

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

The kinesin KIF4 mediates HBV/HDV entry through regulation of surface NTCP localization and can be targeted by RXR agonists in vitro.

S. A. Gad, M. Sugiyama, M. Tsuge, K. Wakae, K. Fukano, M. Oshima, C. Sureau, N. Watanabe, T. Kato, A. Murayama, Y. Li, I. Shoji, K. Shimotohno, K. Chayama, M. Muramatsu, , H. H. Aly

This paper identifies KIF4 as a critical regulator of NTCP surface localization for HBV/HDV entry and shows RXR agonists can suppress KIF4 to inhibit viral infection.

bioRxiv · Sep 29, 2021Microbiology

Comprehensive analysis of full-length transcripts reveal aberrations of splicing variants in liver cancer

H. Kiyose, H. Nakagawa, A. Ono, H. Aikata, M. Ueno, S. Hayami, H. Yamaue, K. Chayama, M. Shimada, J. H. Wong, A. Fujimoto

The paper develops a pipeline to analyze full-length transcripts using long-read sequencing and identifies splicing variants and fusion events in liver cancer.

bioRxiv · Jun 28, 2021Cancer Biology

Aberrant integration of Hepatitis B virus DNA promotes major restructuring of human hepatocellular carcinoma genome architecture

E. G. Alvarez, J. Demeulemeester, C. Jolly, D. Garcia-Souto, P. Otero, A. Pequeno, J. Zamora, M. Tojo, J. Temes, A. Baez-Ortega, B. Rodriguez-Martin, Y. Li, A. Oitaben, A. L. Bruzos, M. Martinez-Fernandez, , J. Tubio

The paper identifies a mutational mechanism in hepatocellular carcinoma driven by Hepatitis B virus DNA integration, leading to genomic restructuring and oncogenic rearrangements.

bioRxiv · Apr 19, 2021Cancer Biology

MafF is an antiviral host factor that suppresses transcription from Hepatitis B Virus core promoter

M. K. Ibrahim, T. H. Abdelhafez, J. S. Takeuchi, K. Wakae, M. Sugiyama, M. Tsuge, M. Ito, K. Watashi, M. El Kassas, T. Kato, A. Murayama, T. Suzuki, K. Chayama, K. Shimotohno, M. Muramatsu, , T. Wakita

This study identifies MafF as an antiviral host factor that suppresses HBV core promoter transcription, contributing to host defense against HBV infection.

bioRxiv · Jul 29, 2020Microbiology

In-depth characterization of the cisplatin mutational signature in human cell lines and in esophageal and liver tumors

A. Boot, M. N. Huang, A. W. T. Ng, S.-C. Ho, J. Q. Lim, Y. Kawakami, K. Chayama, B. T. Teh, H. Nakagawa, S. G. Rozen

This study identifies the mutational signature of cisplatin in human cell lines and tumors, enabling detection of cisplatin exposure in hepatocellular and esophageal cancers.

bioRxiv · Dec 17, 2017Cancer Biology